Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for prevention of episodic cluster headache
NL-OMON47278Phase 3Withdrawn
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in Cluster Headache (CH) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean change from baseline in weekly average number of cluster headache attacks during weeks 0 to 4. Planned start Feb 2017; status: withdrawn.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON47278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47278.